Combination chemo before stem cell transplant for relapsed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug combination to help people with relapsed or refractory acute myeloid leukemia (AML) get ready for a stem cell transplant. The goal is to make the transplant more effective and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) that has come back or did not go away after treatment.
- You are between 18 and 65 years old.
- You are planning to have a stem cell transplant (from a related or unrelated donor).
- You are generally in good health and able to care for yourself (ECOG score 0-2).
- You have not had a stem cell transplant before.
- Your heart, liver, and kidneys are functioning well enough, and you do not have serious infections or certain viral conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three chemotherapy drugs (clofarabine, busulfan, and melphalan) given before a stem cell transplant to treat acute myeloid leukemia (AML) in patients who have responded well to initial treatment. The goal is to improve how well the transplant works and how long patients survive.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
This trial tests a new combination of chemotherapy drugs before a stem cell transplant for people with acute myeloid leukemia (AML) in first remission who are not very fit or have other health problems. The goal is to make the transplant safer for these patients.
This trial tests a new combination of two chemotherapy drugs, melphalan and cladribine, given before a stem cell transplant. It is designed for people with acute myeloid leukemia (AML) that has not responded to treatment or has come back.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests a stronger chemotherapy combination before a donor stem cell transplant for people with certain blood cancers (like AML, MDS, or CMML) that have spread to other parts of the body, such as the skin, testicles, or central nervous system. The goal is to see if this approach can improve outcomes for patients whose disease is in remission.
Hear when a new AML (Acute Myelogenous Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.